European Union - English - EMA (European Medicines Agency)

biotest pharma gmbh - human hepatitis b immunoglobulin - immunization, passive; hepatitis b; liver transplantation - immune sera and immunoglobulins, - prevention of hepatitis b virus (hbv) re-infection in hbsag and hbv-dna negative adult patients at least one week after liver transplantation for hepatitis b induced liver failure. hbv-dna negative status should be confirmed within the last 3 months prior to olt. patients should be hbsag negative before treatment start. the concomitant use of adequate virostatic agents should be considered as standard of hepatitis b re-infection prophylaxis.,

Australia - English - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - human immunoglobulin g, quantity: 3.2 g - injection, solution - excipient ingredients: human immunoglobulin a; glycine - evogam is indicated in adults and children for replacement therapy in: * primary immunodeficiency disease (pid) and * symptomatic hypogammaglobulinaemia secondary to underlying disease or treatment.

Australia - English - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - human immunoglobulin g, quantity: 1.6 g - injection, solution - excipient ingredients: glycine; human immunoglobulin a - evogam is indicated in adults and children for replacement therapy in: * primary immunodeficiency disease (pid) and * symptomatic hypogammaglobulinaemia secondary to underlying disease or treatment.

Australia - English - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - human immunoglobulin g, quantity: 0.8 g - injection, solution - excipient ingredients: glycine; human immunoglobulin a - evogam is indicated in adults and children for replacement therapy in: * primary immunodeficiency disease (pid) and * symptomatic hypogammaglobulinaemia secondary to underlying disease or treatment.

Australia - English - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - human immunoglobulin g, quantity: 20 g - injection, solution - excipient ingredients: human immunoglobulin a; glycine - intragam 10 is indicated for replacement igg therapy in: - primary immunodeficiency disease (pid) - myeloma and chronic lymphocytic leukaemia with severe secondary hypogammaglobulinaemia and recurrent infections - congenital or acquired immune deficiency syndrome with recurrent infections. intragam 10 is indicated for immunomodulatory therapy in: - immune thrombocytopenic purpura (itp), in adults or children at high risk of bleeding or prior to surgery to correct the platelet count - allogeneic bone marrow transplantation - kawasaki disease - guillain-barr? syndrome (gbs) - chronic inflammatory demyelinating polyneuropathy (cidp) - multifocal motor neuropathy (mmn) - myasthenia gravis (mg) in acute exacerbation (myasthenic crisis) or prior to surgery and/or thymectomy; as maintenance therapy for moderate to severe mg when other treatments have been ineffective or caused intolerable side effects - short-term therapy for severely affected nonparaneoplastic lambert-eaton myasthenic syndrome (lems) patients - treatment of significant functional impairment in patients who have a verified diagnosis of stiff person syndrome.

Australia - English - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - human immunoglobulin g, quantity: 10 g - injection, solution - excipient ingredients: glycine; human immunoglobulin a - intragam 10 is indicated for replacement igg therapy in: - primary immunodeficiency disease (pid) - myeloma and chronic lymphocytic leukaemia with severe secondary hypogammaglobulinaemia and recurrent infections - congenital or acquired immune deficiency syndrome with recurrent infections. intragam 10 is indicated for immunomodulatory therapy in: - immune thrombocytopenic purpura (itp), in adults or children at high risk of bleeding or prior to surgery to correct the platelet count - allogeneic bone marrow transplantation - kawasaki disease - guillain-barr? syndrome (gbs) - chronic inflammatory demyelinating polyneuropathy (cidp) - multifocal motor neuropathy (mmn) - myasthenia gravis (mg) in acute exacerbation (myasthenic crisis) or prior to surgery and/or thymectomy; as maintenance therapy for moderate to severe mg when other treatments have been ineffective or caused intolerable side effects - short-term therapy for severely affected nonparaneoplastic lambert-eaton myasthenic syndrome (lems) patients - treatment of significant functional impairment in patients who have a verified diagnosis of stiff person syndrome.

Australia - English - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - human immunoglobulin g, quantity: 5 g - injection, solution - excipient ingredients: human immunoglobulin a; glycine - intragam 10 is indicated for replacement igg therapy in: - primary immunodeficiency disease (pid) - myeloma and chronic lymphocytic leukaemia with severe secondary hypogammaglobulinaemia and recurrent infections - congenital or acquired immune deficiency syndrome with recurrent infections. intragam 10 is indicated for immunomodulatory therapy in: - immune thrombocytopenic purpura (itp), in adults or children at high risk of bleeding or prior to surgery to correct the platelet count - allogeneic bone marrow transplantation - kawasaki disease - guillain-barr? syndrome (gbs) - chronic inflammatory demyelinating polyneuropathy (cidp) - multifocal motor neuropathy (mmn) - myasthenia gravis (mg) in acute exacerbation (myasthenic crisis) or prior to surgery and/or thymectomy; as maintenance therapy for moderate to severe mg when other treatments have been ineffective or caused intolerable side effects - short-term therapy for severely affected nonparaneoplastic lambert-eaton myasthenic syndrome (lems) patients - treatment of significant functional impairment in patients who have a verified diagnosis of stiff person syndrome.

Australia - English - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - human immunoglobulin g, quantity: 2.5 g - injection, solution - excipient ingredients: human immunoglobulin a; glycine - intragam 10 is indicated for replacement igg therapy in: - primary immunodeficiency disease (pid) - myeloma and chronic lymphocytic leukaemia with severe secondary hypogammaglobulinaemia and recurrent infections - congenital or acquired immune deficiency syndrome with recurrent infections. intragam 10 is indicated for immunomodulatory therapy in: - immune thrombocytopenic purpura (itp), in adults or children at high risk of bleeding or prior to surgery to correct the platelet count - allogeneic bone marrow transplantation - kawasaki disease - guillain-barr? syndrome (gbs) - chronic inflammatory demyelinating polyneuropathy (cidp) - multifocal motor neuropathy (mmn) - myasthenia gravis (mg) in acute exacerbation (myasthenic crisis) or prior to surgery and/or thymectomy; as maintenance therapy for moderate to severe mg when other treatments have been ineffective or caused intolerable side effects - short-term therapy for severely affected nonparaneoplastic lambert-eaton myasthenic syndrome (lems) patients - treatment of significant functional impairment in patients who have a verified diagnosis of stiff person syndrome.

Australia - English - Department of Health (Therapeutic Goods Administration)

octapharma australia pty ltd - normal immunoglobulin, quantity: 3300 mg - injection, solution - excipient ingredients: tributyl phosphate; sodium chloride; water for injections; human immunoglobulin a; glycine; polysorbate 80; sodium acetate - replacement therapy in adults and children in primary immunodeficiency syndromes such as: congenital agammaglobulinaemia and hypogammaglobulinaemia, common variable immunodeficiency (cvid), severe combined immunodeficiencies, igg subclass deficiencies with recurrent infections. replacement therapy in myeloma or chronic lymphatic leukaemia with severe secondary hypogammaglobulinaemia and recurrent infections.

Australia - English - Department of Health (Therapeutic Goods Administration)

octapharma australia pty ltd - normal immunoglobulin, quantity: 1650 mg - injection, solution - excipient ingredients: polysorbate 80; water for injections; glycine; tributyl phosphate; human immunoglobulin a; sodium acetate; sodium chloride - replacement therapy in adults and children in primary immunodeficiency syndromes such as: congenital agammaglobulinaemia and hypogammaglobulinaemia, common variable immunodeficiency (cvid), severe combined immunodeficiencies, igg subclass deficiencies with recurrent infections. replacement therapy in myeloma or chronic lymphatic leukaemia with severe secondary hypogammaglobulinaemia and recurrent infections.